Table 2.

The characteristics of eyes in the two groups of treatment at the baseline and at the last available follow-up on treatment.

	Variables	Toc (8 patients)	Aba (10 patients)	Toc vs. Aba
Onset	Median age at the moment of the drug administration	118.5 (65–191)	113.5 (35–151)	0.28
	Median time from disease onset and first administration (range)	67 (29–156)	49.5 (12–127)	0.45
	Duration of therapy median (range)	18 (9–66)	23 (7–97)	0.61
	No. of corticosteroid drops [mean (SD)]	2.13 (1.8)	2 (1.5)	0.3
	No. of patients in systemic corticosteroid	4	5	0.81
	Visual acuity LogMar [mean (SD)]	0	0
	Patients with complications (n)	3	0	0.043
	No. of complications mean (SD)	0.5 (0.756)	0 (0)	<0.001
	Posterior synechiae (n)	1	0	0.27
	Optic disc swelling (n)	3	0	0.11
	Choroid neovascular membrane (n)	1	0	0.27
Last FU	No. of drops of corticosteroid [mean (SD)]	0.25 (0.7)	0.56 (1.33)	0.28
	No. of patients in systemic corticosteroid	0	2	0.15
	Visual acuity [mean (SD)]	0.018 (0.05)	0.0	0.035
	Patients with complications (n)	2	2	0.8
	N° of Complications [mean (SD)]	0.25 (0.4)	0.33 (0.7)	0.42
	Posterior synechiae (n)	1	1	0.9
	Optic disc swelling (n)	1	0	0.25
	Choroid neovascular membrane (n)	1	0	0.25
	Band Keratopathy (n)	1	0	0.38

Bold values are significative results.